切换至 "中华医学电子期刊资源库"
高级检索
中华普外科手术学杂志(电子版)

中华普外科手术学杂志(电子版) ›› 2019, Vol. 13 ›› Issue (05) : 515 -517. doi: 10.3877/cma.j.issn.1674-3946.2019.05.027

所属专题： 文献；

论著

Beclin－1和SIRT－1在大肠癌组织中的表达及意义
东星1,†(), 王晶2, 吕远1   
  1. 1. 100700　解放军总医院第七医学中心普通外科
    2. 解放军总医院第七医学中心妇产科
  • 收稿日期:2019-07-05 出版日期:2019-10-26
  • 通信作者: 东星

The expression and clinical significance of Beclin-1 and SIRT-1 in Colorectal carcinoma

Xing Dong1,†(), Jing Wang2, Yuan Lyv1   

  1. 1. Department of General Surgery, the Seventh Medical Center of PLA General Hospital, Beijing 100700, China
    2. Department of Gynecology and Obstetrics, the Seventh Medical Center of PLA General Hospital, Beijing 100700, China
  • Received:2019-07-05 Published:2019-10-26
  • Corresponding author: Xing Dong
  • About author:
    Corresponding author: Dong Xing, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

东星, 王晶, 吕远. Beclin－1和SIRT－1在大肠癌组织中的表达及意义[J]. 中华普外科手术学杂志(电子版), 2019, 13(05): 515-517.

Xing Dong, Jing Wang, Yuan Lyv. The expression and clinical significance of Beclin-1 and SIRT-1 in Colorectal carcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(05): 515-517.

目的

研究自噬相关基因Beclin－1和沉默信息调节因子－1(SIRT－1)在大肠癌中的表达情况，探讨其在大肠癌发生、发展及预后中的意义。

方法

应用免疫组织化学方法检测Beclin－1和SIRT－1在58例大肠癌、30例大肠腺瘤及30例正常大肠黏膜组织中的表达，并结合临床病理特征进行分析。统计学分析采用SPSS19.0统计软件进行，计数资料采用χ2检验，相关性分析采用Spearman相关分析，P<0.05为差异具有统计学意义。

结果

Beclin－1及SIRT－1在大肠癌组织中的表达率(79.3%，75.9%)显著高于大肠腺瘤(53.3%，50.0%)及正常大肠黏膜组织(20.0%，23.3%)，差异均有统计学意义(P<0.05) 。Beclin－1的表达与大肠癌的临床病理因素均无相关性(P>0.05)。SIRT－1的表达与大肠癌的浸润深度、淋巴结转移、TNM分期呈正相关(P<0.05)。Beclin－1与SIRT－1的表达成正相关(P<0.05) 。Beclin－1和SIRT－1表达阳性的大肠癌患者术后5年生存率明显低于表达阴性者(P<0.05) 。

结论

自噬相关基因Beclin－1和SIRT－1的异常表达在大肠癌的发生中起协同作用，可能作为大肠癌发生、发展、预后的重要判定指标。

关键词: 结直肠肿瘤, 免疫组织化学, 自噬
Objective

To investigate the expression of autophagy-related genes Beclin-1 and SIRT-1 in colorectal carcinoma, and to explore its clinical significance in the occurrence , development and prognosis of colorectal carcinoma.

Methods

The expression of Beclin-1 and SIRT-1 in 58 cases of colorectal carcinoma, 30 cases of colorectal adenomas and 30 cases of normal colorectal tissues were detected by using immunohistochemical methods, and the clinical and pathological characteristics were analyzed. Statistical analysis was carried out by using SPSS19.0 software. The counting data were tested by χ2 test. Spearman correlation analysis was used for correlation analysis. A P value <0.05 was considered as the statistical significant difference.

Results

The expression of Beclin-1 and SIRT-1 in colorectal cancer tissues (79.3%, 75.9%) were significantly higher than those in colorectal adenoma (53.3%, 50.0%) and normal colorectal mucosa tissues (20.0%, 23.3%) respectively with significant difference (all P<0.05). There was no correlation between Beclin-1 expression and clinicopathological factors in patients with colorectal cancer (P>0.05). The expression of SIRT-1 was positively correlated with the depth of invasion, lymph node metastasis and TNM stage of colorectal cancer (P<0.05). Beclin-1 expression was positively correlated with SIRT-1 expression (P<0.05). The 5-year survival rate of patients with positive expression of Beclin-1 and SIRT-1 was significantly lower than that of patients with negative expression of Beclin-1 (P<0.05).

Conclusions

Abnormal expression of autophagy-related genes Beclin-1 and SIRT-1 plays a synergistic role in the occurrence, development and prognosis of colorectal cancer.

Key words: Colorectal neoplasms, Immunohistochemistry, Autophagy
图2 Beclin－1在大肠腺瘤中的阳性表达(SP×200)
图4 SIRT－1在大肠腺瘤中的阳性表达(SP×200)
表1 58例大肠癌组织中Beclin－1与SIRT－1的表达和临床病理因素的关系
病理因素 例 Beclin\1 SIRT－1
＋ χ2 P ＋ χ2 P
性别 ? ? ? ? ? ? ?
? 男 37 31 1.246 0.264 27 0.466 0.495
? 女 21 15 17
年龄(岁) ? ? ? ? ? ? ?
? ≤40 22 15 2.675 0.102 16 0.190 0.663
? > 40 36 31 28
肿瘤大小 ? ? ? ? ? ? ?
? ≤3 cm 39 30 0.414 0.520 31 0.854 0.355
? > 3 cm 19 16 13
分化程度 ? ? ? ? ? ? ?
? 高中分化 32 23 2.405 0.121 23 0.619 0.431
? 低分化 26 23 21
浸润深度 ? ? ? ? ? ? ?
? 粘膜或浅肌层 26 18 2.918 0.088 16 5.280 0.022
? 深肌层或全层 32 28 28
淋巴结转移 ? ? ? ? ? ? ?
? 无 30 21 3.283 0.070 19 5.327 0.021
? 有 28 25 25
TNM分期 ? ? ? ? ? ? ?
? Ⅰ期 10 6 4.601 0.204 4 9.792 0.020
? Ⅱ期 21 18 16
? Ⅲ期 22 19 20
? Ⅳ期 5 3 4
[1]
Levy JMM,Towers CG,Thorburn A．Targeting Autophagy in Cancer[J]. Nat Rev Cancer, 2017, 17(9): 528－542.
[2]
Monkkonen T,Debnath J. Inflammatory signaling cascades and autophagy in cancer[J]. Autophagy, 2018, 14(2): 190－198.
[3]
Avraham A,Bento CF,Ricketts T, et al.Polyglutamine tracts regulate beclin 1－dependent autophagy[J]. Nature, 2017, 545(7652): 108－111.
[4]
Qu H,Li T,Jin H, et al. Silent Mating Type Information Regulation 2 Homolog (SIRT1) Influences Osteogenic Proliferation and Differentiation of MC3T3－E1 Cells via Regulation of miR－132－3p[J]. Med Sci Monit, 2019, 25(3): 2289－2295.
[5]
Dusabimana T,Kim SR,Kim SR, et al. Nobiletin ameliorates hepatic ischemia and reperfusion injury through the activation of SIRT－1/FOXO3a－mediated autophagy and mitochondrial biogenesis[J]. Exp Mol Med, 2019, 51(4): 51.
[6]
Galluzzi L,Pietrocola F,Bravo－San Pedro JM, et al. Autophagy in malignant transformation and cancer progression [J]. EMBO J, 2015, 34(7): 856－880.
[7]
Weh KM,Howell AB,Kresty LA. Expression, Modulation, and Clinical Correlates of the Autophagy Protein Beclin－1 in Esophageal Adenocarcinoma[J]. Mol Carcinog, 2016, 55(11): 1876－1885.
[8]
Bao LJ,Jaramillo MC,Zhang ZB, et al. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma[J]. Int J Clin Exp Pathol, 2014, 7(4): 1502－1513.
[9]
Liu C,Xu P,Chen D, et al. Roles of autophagy－related genes Beclin－1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia[J]．Biomed Rep, 2013, 1(6): 855－860.
[10]
Qin Z,Yu X,Lin M, et al. Prognostic and clinicopathological value of Beclin－1 expression in hepatocellular carcinoma: a meta－analysis[J]. World J Surg Oncol, 2018, 16(1): 170－170.
[11]
吴淑华，胡金龙，何双，等. 大肠癌中Beclin1、LC3和mTOR的表达及意义[J]. 临床与实验病理学杂志，2014，30( 12): 1333－1338.
[12]
Bo S,Togliatto G,Gambino R, et al. Impact of sirtuin－1 expression on H3K56 acetylation and oxidative stress: a double－blind randomized controlled trial with resveratrol supplementation[J]. Acta Diabetol, 2018, 55(4): 331－340.
[13]
Li S,Hong H,Lv H, et al. SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells[J]. Med Sci Monit, 2016, 22(5): 1593－1600.
[14]
Sharma A,Gautam V,Costantini S, et al. Interactomic and Pharmacological Insights on Human Sirt－1[J]. Front Pharmacol, 2012, 3(3): 40.
[1] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635.
[2] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[3] 周子慧, 李恭驰, 李炳辉, 王知, 刘慧真, 王卉, 邹利军. 细胞自噬在创面愈合中作用的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 542-546.
[4] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[5] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[6] 付佳, 肖海敏, 武曦, 冯涛, 师帅. 年龄校正查尔森合并症指数对腹腔镜结直肠癌围手术期并发症的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 336-341.
[7] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[8] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[9] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[10] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[11] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[12] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[13] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[14] 王小红, 钱晶, 翁文俊, 周国雄, 朱顺星, 祁小鸣, 刘春, 王萍, 沈伟, 程睿智, 秦璟灏. 巯基丙酮酸硫基转移酶调控核因子κB信号介导自噬对重症急性胰腺炎大鼠的影响及机制[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 422-426.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号